**Mycobacterium avium-intracellulare infection during HIV disease. Persisting problems**

Roberto Manfredi  
*Department of Infectious Diseases, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Hospital, Bologna-Italy*

**Key words:** HIV disease, Opportunistic infections, Combined antiretroviral therapy, Mycobacterium avium-intracellular, Diagnosis, Treatment, Prophylaxis

**SUMMARY**

Still in the era of combined antiretroviral therapy, late recognition of HIV disease or lack of sufficient immune recovery pose HIV-infected patients at risk to develop opportunistic infections by nontuberculous mycobacteria (NTM), which are environmental organisms commonly retrieved in soil and superficial waters. Among these microorganisms, the most frequent is represented by *Mycobacterium avium* complex (MAC). Health care professionals who face HIV-infected patients should suspect disseminated mycobacterial disease when a deep immunodeficiency is present, (a CD4+ lymphocyte count below 50 cells/µL) often associated with constitutional signs and symptoms, and non-specific laboratory abnormalities. Mycobacterial culture of peripheral blood is a reliable technique for diagnosing disseminated disease. Among drugs active against NTM, as well as some anti-tubercular compounds, the rifampin derivative rifabutin, and some novel fluoroquinolones, the availability of macrolides, has greatly contributed to improve both prophylaxis and treatment outcome of disseminated MAC infections. Although multiple questions remain about which regimens may be regarded as optimal, general recommendations can be expressed on the ground of existing evidences. Treatment should begin with associated clarithromycin (or azithromycin), plus ethambutol and rifabutin (with the rifabutin dose depending on other concomitant medications that might result in drug-drug interactions). A combined three-drug regimen is preferred for patients who cannot be prescribed an effective antiretroviral regimen immediately. Patients with a CD4+ lymphocyte count below 50 cells/µL, who do not have clinical evidence of active mycobacterial disease, should receive a primary prophylaxis with either clarithromycin or azithromycin, with or without rifabutin.

**Received June 9, 2008**  
**Accepted August 4, 2008**

**INTRODUCTION**

*Mycobacterium avium-intracellulare* complex (MAC) consists of acid-fast microorganisms ubiquitous in the environment that are an infrequent cause of disease in individuals with normal immune defence. In deeply immunocompromised patients, such as those with advanced HIV infection-AIDS, MAC still represent common and serious opportunistic infections (12, 44). Among HIV-infected subjects followed in the pre-antiretroviral therapy era, disseminated MAC has historically occurred when the CD4+ T-lymphocyte count dropped at values <50 cells/µL (12, 44). Colonization of the airways (and also the gastrointestinal tract) by MAC can occur without evident morbidity; however, MAC colonization of these sites underlines that such patients are at increased risk for developing disseminated MAC infection (13). The combination antiretroviral therapies (cART) introduced since mid-1996, have been associated with a significant reduction in AIDS-related mortality, days of hospitalization, and the incidence of recurring opportunistic infections, including MAC disease (48). However, since the introduction of cART (3, 29, 41, 50, 52, 57), there have been numerous reports of atypical MAC clinical presentations, so that diagnosis remains still difficult. The diagnosis can pose challenges to the clinician because isolation of these organisms is often difficult. In addition, both active disease and airway colonization occur in individuals with structural defects, previous or concurrent illnesses, adding further confusion for health caregivers. Furthermore, these organisms are frequently contaminants, leading to false-positive diagnoses in patients with other active diseases. The treatment...
of non-tuberculous mycobacteria (NTM) infections is as difficult as establishing a correct diagnosis because therapy is often prolonged, difficult to tolerate, and frequently ineffective. In this context, clinicians should be familiar with these emerging disorders, whose incidence may increase among immunocompromised patients other than those with HIV/AIDS (12). There is convincing evidence that an effective treatment of disseminated MAC infection improves both survival and quality of life of patients with HIV infection (55). Whether MAC can be eradicated once disseminated infection has occurred is still uncertain, but some evidences suggest that secondary prophylaxis may be discontinued in patients who have had sustained immunologic recovery further to an effective cART (1, 2, 80).

**Microbiological and epidemiological notes**

*Mycobacterium avium-intracellulare* complex (MAC) consists of four recognized species (*Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium chimaera, Mycobacterium colombiense*) and several unnamed organisms not belonging to any of these taxa referred to as cluster X or MAIX. In the past, it was difficult to distinguish *M. avium* from *M. intracellulare*, as species identification relied on biochemical tests and serotyping. Therefore, it was common to refer to them as *M. avium-intracellulare*. Of the 28 known seroagglutination MAC types, types 1 to 6, types 8 to 11, and type 21 are classified as *M. avium*; type 7, types 12 to 20, and type 25 are classified as *M. intracellulare*; while types 22 to 24 and types 26 to 28 have not been classified until recent years (60). Using DNA probe techniques, it is now possible to rapidly identify *M. avium* and *M. intracellulare* (39). However, in most cases of AIDS-related disease, disseminated MAC infection is caused by *M. avium* species, and from a therapeutic-prophylactic point of view no significant difference occur. MAC strains may vary in their pathogenicity, which may explain why *M. avium* serotypes 4 and 8 are the most common organisms to infect immunocompromised patients suffering from AIDS (61, 77). Some identified biological markers of MAC pathogenicity include the presence of plasmid, antibiotic susceptibility patterns, multilocus enzyme electrophoresis profiles, and restriction fragment length polymorphism patterns (16, 26, 30). Furthermore, changes in colony morphology may play a role in influencing the virulence of some NTM species, with special focus on MAC, with smooth versus rough morphotypes potentially associated with more virulent, invasive clinical pictures (33, 37). Superficial water, soil and dust have been implicated as possible environmental sources of MAC for HIV-infected patients (as in the general population). During a documented nosocomial outbreak, the hospital water supply was the ascertained origin of a well defined MAC strain, with showed the same restriction fragment length polymorphism profile as that infecting a group of hospitalized AIDS patients (66). Furthermore, no apparent differences have been observed in the frequency of disseminated MAC infection according to age, gender, geographic areas, the different exposure to HIV infection transmission, antiretroviral therapy selection, and initial AIDS-defining conditions (32).

**Pathogenesis and pathologic features**

The mechanisms of spread and acquisition of disseminated MAC infection are still incompletely understood. As such, not all NTM isolates represent true infections, since they may be trivial colonization or contamination. Currently available data support the hypothesis that MAC disease results from recent environmental transmission through either the respiratory or the gastrointestinal tract, rather than from a reactivation of latent MAC infection. Should reactivation of latent infection occur as the prevalent, it would be expected to increase with age, like in tuberculosis. On the contrary, among HIV-infected patients with a primary disease manifestation, the occurrence of MAC dissemination does not vary within different age groups (32). Anyway, after acquiring a clinically evident MAC infection, underlying immunodeficiency becomes the most relevant factor, which supports disease recurrences during the follow-up. From an immunological point of view, the risk of developing HIV-associated MAC infection is inversely related with the absolute CD4+ lymphocyte count. In one observational study, the measured one-year incidence of MAC bacteremia was 3% for patients with a CD4+ count ranging from 100 to 199 cells/µL, as compared with 39% for patients with a CD4+ count <10 cells/µL (44). The same study also underlined that individuals with a far advanced HIV disease had a linear increase in the risk of developing MAC bacteremia over time, and the risk of developing disseminated MAC infection for patients surviving for 30 months after being diagnosed with AIDS was around 50% (44). Other observational studies and prophylaxis trials added several, consistent findings: the risk of developing a disseminated MAC disease ranged from 30% to 50% in patients with CD4+ lymphocyte counts <50 cells/µL which did not undergo specific antimicrobial prophylaxis (12, 45, 51). In particular, the difficulty to demonstrate a retrievable antibody response to MAC in HIV-infected patients with disseminated MAC infection may...
also suggests a recent primary infection, because deeply immunocompromised HIV-infected patients lack the ability to establish antibody responses to multiple, primary infections (69, 70). Furthermore, literature reports of MAC colonization of the respiratory or gastrointestinal tract preceding the occurrence of disseminated MAC infection suggest that the organism is first acquired from the environment and subsequently disseminated, when a severe underlying immunosuppression is present (13, 36). Finally, the incidence of disseminated MAC disease among patients with AIDS substantially exceeds the frequency of MAC infection in the general population, as determined by population studies, and confirmed also by MAC-specific skin testing (65). By the year 1984, only 37 cases of disseminated MAC infection in non-HIV-infected humans were reported, the majority of them in patients with identifiable, severe immunological deficiencies (31). In the non-HIV population, MAC infection generally caused localized lesions: cervical lymphadenitis in children, a slowly progressive fibrocavitary pulmonary disease in middle-aged men with a chronic, underlying lung disease, or localized bronchiectasis in women who had pectus excavatum, scoliosis, or mitral valve prolapse and associated conditions (i.e. Marfan’s syndrome) (35, 71). The blunted immune response and the lack of local and systemic inflammatory reaction typical of patients with AIDS and a deep HIV-related immunodeficiency who develop disseminated MAC disease is consistent with the hypothesis that the key immunologic defects associated with dissemination relies on an unpaired monocyte-macrophage killing of mycobacteria and a defective cytokine network response, including abnormally low levels of tumor necrosis factor (TNF), interferon-gamma, and interleukin-12 (4, 9, 18, 42, 79). As a result of this extremely permissive immunological environment, MAC infection becomes widespread in extremely immunosuppressed HIV-infected patients, and it was the case of most subjects suffering from MAC disease during the pre-cART era. In the majority of autopsy examinations performed in patients who died of MAC infection in the pre-cART era, mycobacteria have been isolated from lymph nodes, spleen, liver, lung, adrenal glands, gastrointestinal tract, kidney, and bone marrow, but multiple dissemination has virtually no limits, and may involve all body organ-sites. In fact, the magnitude of mycobacteremia has been estimated to be as high as 10,000 organisms/µL of blood, the equivalent of 10 billion organisms per gram of bone marrow, spleen, lymph node, and liver tissue obtained at necropsy examination (72). Not surprisingly, the histopathologic examination of liver, spleen, bone marrow, or gut from patients with AIDS-related disseminated MAC disease shows a high-grade widespread infection, together with a lack (or reduced) inflammatory infiltrate or tissue necrosis. In contrast, histopathologic examination of tissue from patients with AIDS who have localized MAC infection demonstrates marked inflammatory reaction and tissue destruction similar to the histopathologic findings observed in association with non-HIV MAC infections. On the other hand, the rapid recovery of immune defences obtained following cART introduction, is the basis of the so-called immune-reconstitution syndrome, which is more prominent just in patients with a prior-latent, or a recently acquired MAC infection.

Clinical Presentation
Subjects suffering from a disseminated MAC infection frequently show non-specific signs-symptoms, and multiple laboratory abnormalities. In many instances, a progressive worsening of constitutional symptoms may reflect a disseminated MAC infection, and this aspect can be incorrectly referred as to the progression of HIV disease itself. Patients affected by MAC disease most commonly report persistent fever (not responding to a broad-spectrum empiric antibiotics), night sweats, asthenia, fatigue, anorexia, and weight loss up to cachexia (the so-called wasting syndrome). Non specific abdominal pain or chronic diarrhoea, may result from the involvement of retroperitoneal lymphnodes or gastrointestinal mucosa, respectively, by disseminated MAC disease A considerable liver and lymphnodes enlargement as demonstrated by abdominal computed tomography (CT) and ultrasonographic studies may also complete the clinical picture (47). From a laboratory point of view, pancytopenia is the most common occurrence, while elevated serum alkaline phosphatase and lactic dehydrogenase levels, or low albumin levels have been also reported. In a prospective, observational survey of MAC bacteremia conducted at a single-centre US Hospital during the pre-cART era, the Authors interviewed patients with a CD4+ count <50 cells/µL regarding signs and symptoms, and reviewed the laboratory workup conducted as part of the diagnostic evaluation for disseminated MAC infection (13). A history of fever lasting for more than one month, a hematocrit under 30%, or serum albumin levels below 3.0 g/100 ml, proved affordable predictors of MAC bacteremia. On the other hand, fatigue, diarrhoea, weight loss, neutropenia, and thrombocytopenia did not seem to play a significant role in discriminating between patients who were subsequently found to have MAC-positive blood cultures, and those who were culture-negative for MAC (13). More unusual
manifestations of visceral MAC infection include a broad spectrum of localizations, including oral (palatal-gingival) ulcerations, septic arthritis, osteomyelitis, endophthalmitis, pericarditis, and gastrointestinal bleeding (7, 8, 14, 64, 73). NTM lung infection is almost always associated with symptoms such as chronic or recurring cough, sputum production, and exertional dyspnea. Although uncommon, haemoptysis can occur, thus entering tuberculosis in the differential diagnosis. However, also in patients with a suspected respiratory localization, constitutional symptoms occur, and often predominate.

**Diagnosis and microbiological workup**

The diagnosis of disseminated MAC disease frequently poses severe challenges to the clinicians. As recovery of these microorganisms may represent airway colonization, rather than true infection, diagnosis must be based on the compatibility between a high clinical suspicion (symptoms, clinical features, imaging) and microbiological findings. When a respiratory localization is suspected, sputum cultures are not reliable since they are often negative, and bronchial washing (or preferably BAL) samples, may be a more useful diagnostic tool. According to the American Thoracic Society criteria (25), a single positive culture from bronchial washing or BAL specimens may be considered diagnostic. Tissue fragments obtained from biopsy studies (transbronchial lung biopsy, surgical lung biopsy, or excision biopsy from infected tissues), are also diagnostic if they lead to the isolation of MAC organisms or show granulomata on histopathologic examination. Should culture be negative despite an high degree of clinical suspicion, it must be repeated in order to achieve an etiologic diagnosis. Finally, tuberculosis must be excluded in all cases of suspected MAC, especially when pulmonary infiltrates and acid-fast bacilli smear positivity are recognized. With regard to patients with advanced HIV infection, systematic culture search of MAC from peripheral blood is a sensitive and easy method for diagnosing disseminated MAC infection. Mycobacterial blood cultures allow to establish the diagnosis of disseminated MAC disease with a very good sensitivity (86% to 98% of cases in which disseminated MAC infection was subsequently confirmed at necropsy examination) (28, 67). While one blood culture leads to identify around 90% of HIV-infected patients with MAC bacteremia, the adjunct of a second blood culture increases the identification rate up to 98% (53, 74). Blood seeding into liquid and solid media is usually preceded by a lysis of peripheral blood leukocytes, to release intracellular mycobacteria (Isolator System) (23, 54). Using liquid culture media, MAC can be detected from blood cultures in as few as 6-12 days, whereas 15-40 days are required with the traditional solid media. Furthermore, currently available DNA probes and reverse hybridisation PCR assays can identify and distinguish among MAC species within as few hours, after that a sufficient mycobacterial growth has occurred in culture media (23, 39). In addition, tissue biopsies obtained from normally sterile body sites are also diagnostic. For example, histological stain of biopsy specimens obtained from bone marrow, lymph nodes, or liver showing acid-fast bacilli or tuberculous-like granulomata, may be observed several weeks before blood culture results become available (42, 43). It is also possible that cultures of bone marrow, lymph node, or liver, could be more sensitive in comparison with blood cultures, especially when a chronic disease has been already established, and a deep immunodeficiency occur.

**Therapeutic management of MAC infection in the setting of HIV disease**

The treatment of disseminated MAC disease is seldom straightforward, especially in the field of HIV infection and AIDS. Diagnostic uncertainty is common, prolonged durations of therapy are frequently needed, and eradication is unlikely. Moreover, treatment regimens are expensive, and are often poorly tolerated because of frequent side effects, while the drug-drug interaction with multiple compounds frequently co-administered frequently affects patient with HIV disease (12). As known, NTM are not killed by standard antituberculous drugs at *in vivo* achievable plasma concentrations with the exception of ethambutol. However, based on extensive observational *in vitro* testing, at least 50% of MAC strains can be inhibited by achievable serum levels of some antimicrobial drugs, including rifabutin, rifampin, clofazimine, cycloserine, amikacin, ethionamide, azithromycin, clarithromycin, ciprofloxacin, sparfloxacin, and moxifloxacin. Unfortunately, plasma drug levels needed to obtain a complete *in vitro* killing of MAC (the so-called minimum bactericidal concentration, or MBC value) range from 8 to ≥32 times compared with minimum inhibitory levels (minimum inhibitor concentration, or MIC value) (76). While associated antimycobacterial agents have shown *in vitro* inhibitory synergism, a truly bactericidal synergism has been more difficult to be demonstrated (22, 34). Moreover, in order to ensure *in vivo* bactericidal activity, drugs must penetrate mononuclear cells (especially macrophages) at a suitable concentrations, and must ensure levels capable to pass the bacterial cell wall of MAC organisms. Anyway, some relia-
ble animal models of disseminated MAC infection showed that both single and combination antimycobacterial regimens led to reduced mycobacterial colony counts by several logs, and also improved survival (22, 34). Medical therapy for disseminated MAC disease involves multiple agents, in order to facilitate clearance of organisms, and to minimize drug resistances. The cornerstone agents include macrolides, ethambutol, and the rifamycin derivative rifabutin (12). Three-drug regimens are preferred because of concerns for the development of macrolide resistance. In fact, some last-generation macrolides, in particular clarithromycin and azithromycin, showed in vitro and in vivo efficacy against MAC. A multicenter, randomized, placebo-controlled trial performed in the pre-cART era, assessed clarithromycin monotherapy, in dosages of 500, 1000, and 2000 mg (all twice daily), in patients with a primary diagnosis of disseminated MAC. The investigators reported a median decrease of over 2 logs in bacterial colony-forming units from blood culture specimens, thus demonstrating a more potent microbiologic effect than had been reported in earlier trials, together with an affordable in vivo response (10). However, a dose-response effect was not observed, but elevated gastrointestinal intolerance occurred with the 2000-mg dosage. Although the 1000-mg twice-daily dosage led to a greater microbiologic response versus the 500-mg twice-daily dosing, there was a trend towards an increased mortality in association with the 1000-mg dosage (10). It was not surprising that after 2-3 months of macrolide administration (regardless of dosages), drug resistance emerged involving about 50% of patients. Although daily therapy is strongly recommended, for patients who cannot tolerate daily therapy or those who do not require an aggressive treatment strategy, intermittent (three times-weekly) therapy may be adequate. Macrolides administration should be combined with at least another antimycobacterial agent, in order to prevent or delay the emergence of resistance, which is strongly associated with clinical deterioration, and a less favourable outcome.

Another study confirmed that the 1000-mg twice-daily dosage of clarithromycin has an adverse effect on survival compared with the 500 mg twice-daily dosing (15). In a trial of azithromycin monotherapy, patients with newly diagnosed positive MAC blood cultures received randomized administration of 1 of 2 doses of azithromycin, 600 or 1200 mg daily. After six weeks, approximately one half of blood cultures were sterile in both groups, with a mean reduction in mycobacteremia of 2 and 1.55 logs, respectively (40). As already observed with clarithromycin, the higher dosage of azithromycin was related to a higher rate of gastrointestinal intolerance. A number of other antimycobacterial agents has been assessed in several randomized, controlled trials. In one trial performed before the introduction of cART, investigators compared the microbiologic efficacy of four-week monotherapy regimens of rifampin, ethambutol, or clofazimine in patients with previously untreated disseminated MAC (38): only ethambutol achieved a statistically significant reduction in blood MAC colony-forming units, suggesting that ethambutol might be the most potent of these three agents. A rifampin derivative, rifabutin, had been specifically developed for the management of disseminated MAC infection in the immunocompromised patient (38). In an early randomized, placebo-controlled trial in which patients with newly diagnosed disseminated MAC disease were blindly assigned to receive clofazimine/ethambutol or clofazimine/ethambutol/rifabutin (at 600 mg/day), approximately half of the patients receiving the rifabutin-containing regimen had a >2 log decrease in blood MAC colony-forming units, or sterilization of the blood, compared with none of those receiving only clofazimine/ethambutol combination (59). The long-term clinical outcome of combination regimens including both macrolide and non-macrolide agents for treatment of disseminated HIV-associated MAC disease, was confirmed in a randomized multicenter trial published in 1996 (55). This study included 187 patients with ascertained MAC mycobacteremia, who were randomized to receive clarithromycin at 1,000 mg twice daily, rifabutin 300-600 mg once daily, and ethambutol 15 mg/kg/day, or a regimen of ciprofloxacin 750 mg twice daily, rifampin 600 mg once daily, clofazimine 100 mg once daily, and ethambutol 15 mg/kg/day (55) The in vivo quantitative antimycobacterial efficacy tested significantly better with the macrolide-containing regimen, as was median patients’ survival (8.6 versus 5.2 months; p<.001). Although multiple investigations contributed with the evidence of positive results, the composition of the optimal treatment regimen for disseminated MAC in patients with HIV disease is still uncertain. Based on the available microbiological and clinical data, a macrolide drug (either clarithromycin or azithromycin), should be part of the regimen. No significant differences in mortality rates was noticed in a randomized, double-blind trial comparing azithromycin at 600 mg once daily with clarithromycin 500 mg orally twice a day, in an ethambutol-based regimen (20). Evidences coming from a trial of several clarithromycin-containing regimens suggested that clofazimine compared poorly with ethambutol as a second drug added to clarithromycin (18). Furthermore, a randomized clinical trial that added
cl clofazimine to clarithromycin plus rifabutin found a greater mortality rate in the clofazimine-containing arm (62% with clofazimine versus 38% without clofazimine; \( p=0.012 \)) (11). Another randomized trial which assessed a four-drug, oral antimycobacterial regimen with or without amikacin showed no clinical benefit associated with the additional amikacin schedule (49). A large, open-label, prospective, randomized trial comparing the efficacy and safety of clarithromycin plus ethambutol, rifabutin, or both for the treatment of disseminated MAC was conducted in 2003 (6). Of the 203 enrolled patients, 53 received clarithromycin and ethambutol, 50 received clarithromycin and rifabutin, and 57 received all three drugs. A complete microbiologic response (as defined by sterile blood cultures at 12 weeks), was found in 40%, 42% and 51% of cases, respectively. Notably, a significant improvement in survival was observed in the three-drug arm. Anyway, another randomized, placebo-controlled study which assessed the addition of rifabutin to a regimen of clarithromycin and ethambutol did not find any difference in the microbiologic response or survival benefit between the two stated arms (24). Moreover, this last study detected a significant reduction in the development of clarithromycin resistance in the arm containing three drugs (2% versus 14%), thus suggesting a benefit in the field of microbial resistance. Macrolide resistance occurs during macrolide monotherapy, although the concomitant use of fluoroquinolones has been suggested as an adjunctive supporting cause. Although both fluoroquinolones and carbapenems have been reported to be effective in vitro and in vivo against a broad spectrum of NTM (17, 68, 78), the combination usage does not allow to distinguish the contribution of each single agent, when in vivo therapeutic courses are assessed (17). Regimens that do not include ethambutol are also associated with the development of drug resistance. Unfortunately, in cases of macrolide resistance, mortality occurs within one year in approximately one third of patients and, nearly half of patients will die within two years (12). In the immunocompromised host, treatment should be continued for up to 12 months; negative sputum cultures should be obtained in pulmonary localizations. Therefore, the typical duration of treatment may range from 18 to 24 months, but it can be even longer for some individuals, whose immune recovery is slow. Also in the cART era, treatment failure and recurrences of disseminated MAC disease may occur. Patients are considered to have a treatment failure if they did not show clinical improvements after six months of appropriate treatment, or did not achieve negative sputum culture after 12 months of appropriate therapy (in the event of isolated respiratory tract disease).

Treatment failure may be related to non-compliance or intolerance, local anatomic defects (cavitations or bronchiectasis, in case of lung disease), or drug resistance (especially to macrolides). In selected cases of disseminated NTM infections (i.e. the forms related to the so-called immune reconstitution syndrome occurring in AIDS patients effectively treated with antiretroviral therapy), steroid adjunct may act favourably (58, 62, 63). Relapses and re-infections are also common, and may not be necessarily related to drug resistance. Patients showing treatment failures are unlikely to have a successful course of re-treatment. Therefore many authors advocate aggressive treatment initially. Surgical resection may be effective in patients with focal (especially pulmonary) MAC disease, and it is considered the treatment of choice for solitary pulmonary nodules.

**Antimycobacterial prophylaxis guidelines**

Since up to 40% of patients with advanced HIV disease are likely to develop disseminated MAC, it makes sense to develop a strategy for preventing this disease in patients at risk (the so-called primary prophylaxis). Few specific risk factors, other than a low CD4+ lymphocyte count, have been clearly defined until now. Therefore, any current prophylactic strategy must be applied to the entire population at risk including patients with HIV infection and a CD4+ count <50 cells/µL. Results of combined analysis of two randomized, placebo-controlled trials of rifabutin prophylaxis carried out in the pre-cART era, which included more than 1,000 patients with advanced HIV disease, showed that rifabutin at 300 mg/day reduced the incidence of mycobacteremia by about 50% (45). Interestingly, patients who received rifabutin and subsequently developed mycobacteremia, had blood MAC isolates that retained susceptibility to rifabutin. However, neither each single trial, nor their combined analysis, demonstrated that rifabutin significantly reduced mortality. Combined analysis of both trials revealed an increased incidence of fever, fatigue, anaemia, elevated alkaline phosphatase levels, and hospitalizations, in patients who received placebo versus those who received rifabutin. Patients assigned to the placebo arm in these last trials, however, tended to have a lower absolute CD4+ count, which may have accounted for some of the greater morbidity (45). A further placebo-controlled study provided the first evidence that MAC prophylaxis could improve survival of patients with late-stage HIV disease. Six hundred and 82 patients with advanced HIV disease were randomly assigned to receive either clarithromycin (500 mg) or placebo twice daily. During a
median 10-month follow-up period, only 6% of clarithromycin-treated subjects developed mycobacteremia compared with 16% of placebo-assigned patients (p<.001) (51). Notably, the median patients’ survival time was significantly longer for clarithromycin-assigned patients than for placebo-assigned patients (8.6 versus 5.2 months; p=.001). Dose-limiting drug toxicity occurred in 8% of the clarithromycin group, and 6% of the placebo group. A prior trial had already provided even more convincing evidence of the long-term benefit of clarithromycin prophylaxis for MAC in patients with very advanced HIV disease. A total of 1,216 patients with a median absolute CD4+ lymphocyte count of 28 cells/µL were randomly assigned to receive rifabutin (300-450 mg/day), clarithromycin (500 mg twice daily), or their association (5). Median follow-up of patients enrolled in this trial was 589 days (over 19 months), longer than in any other MAC prophylaxis trial ever performed; overall survival was approximately 50%. At the conclusion of the trial, deaths in the respective groups were: clarithromycin, 42%; rifabutin, 43%; and the combination, 46%. In an intent-to-treatment analysis, only 9% of patients assigned to clarithromycin developed disseminated MAC, compared with 15% assigned to rifabutin (p<.001). In a third macrolide prophylaxis trial, 693 patients with less than 100 CD4+ cells/µL were randomly assigned azithromycin (1,200 mg once weekly), rifabutin (300 mg/day), or a combination of these drugs (27). During the median follow-up time of 514 days, the incidence of disseminated MAC proved lower in the azithromycin group (13.9%) or the combination group (8.3%) versus that one observed in subjects receiving rifabutin only (23.3%). Dose-limiting drug toxicity occurred in 13%, 23%, and 16% of the three stated patient groups, respectively (27). Interestingly, the occurrence of macrolide-resistant MAC disease has been an infrequent event in the reported prophylaxis studies: only 2-3% of patients given clarithromycin and only 1% of patients given azithromycin suffered from an mycobacteremia with MAC isolates resistant to these drugs. In the 2000, two randomized, controlled studies have compared azithromycin with placebo in patients with a CD4+ count increased to at least 100 cells/µL while on a potent cART treatment, and no prior history of disseminated MAC disease (13). In a study, a total of 520 patients were enrolled with a median CD4+ count of 230 cells/µL at the time of entry. There were no cases of confirmed MAC in either the azithromycin arm or the placebo arm over a 12-month observation period (11). In another study, which enrolled 643 patients, only two episodes of MAC disease were observed among the 321 patients assigned to pla-
REFERENCES


5. Benson CA, Williams PL, Cohn DL, et al. A study of discon-


18. Denis M, Gregg EO. Reombinant tumour necrosis factor-alpha decreases whereas reombinant interleu-


22. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clari-


24. Gordin FM, Sullam PM, Shafran SD, et al. A randomi-


26. Hampson SJ, Portaels F, Thompson J, et al. DNA pro-


58. Tortoli E, Rindi L, Garcia MJ, et al. Proposal to elevate the genetic variant MAC-A included in the Mycobacterium avium complex, to species rank as...


